Therefore, we here describe for the first time the development of two novel RevTMs and their successful application for targeting of Fn14-positive GBM cells both in vitro and in vivo using switchable RevCAR T and RevCAR NK-92 cells. This evidence concerns the gene TNFRSF12A and glioblastoma.